A person can meet every eligibility criterion in a protocol and still be unable to take part because of parking fees, childcare, unpaid time off, or a missing internet connection. Those costs build an invisible wall around clinical trials, and it shuts out many of the people who need them most. The damage is not only individual. Trials that exclude people on income skew the evidence they produce, and the data will not fully represent the population it is meant to serve. Addressing this inequity is not just fair. It is a condition of reliable science.
Socioeconomic status plays a central role in determining who gets through the door. People from lower-income backgrounds, often facing systemic inequities, are more likely to find trial participation financially out of reach. This is particularly troubling because these same populations frequently bear a greater burden of disease. Closing the gap means confronting financial obstacles head-on and rethinking how we design and support clinical trials. Real change starts when we acknowledge these invisible costs and act to reduce them.
Researchers and sponsors must recognize that removing financial barriers is not just generous. It is strategic. Compensation for time, travel reimbursements, and logistical support increase both enrollment and retention. More importantly, these measures send a message: every person’s time and health are valued. Transparent and fair compensation should be standard protocol, not an afterthought. Providing this kind of support turns trials from exclusive opportunities into inclusive ones.
Beyond individual costs, institutional policies often compound the problem. Participants may lose access to public benefits if reimbursed incorrectly. Lack of coordination between trial organizers and social service systems creates additional stress for people who already feel vulnerable. It is vital that trial policies are designed with these realities in mind. Consultation with community organizations, patient advocates, and social workers can help ensure financial support does not create unintended harm.
Tackling Financial Barriers With Smart Trial Design
Trial access is shaped by geography as much as by income. Rural patients often travel long distances to reach study sites, while urban participants may face steep transit costs or inflexible work schedules. Hybrid and decentralized trials can reduce some of these burdens by allowing more activities to take place remotely. These models are not one size fits all, though. Digital access, tech literacy, and comfort with remote monitoring vary widely. Including patients in trial design helps uncover which formats are practical and where more support is needed.
The connection between socioeconomic disparity and trial participation is not abstract. Studies show that people of color, who are disproportionately affected by poverty, are underrepresented in trials. This results in treatments that may be less effective, or even unsafe, for the very groups most affected by disease. Closing this gap requires proactive strategies, such as reaching people through trusted community networks and offering flexible compensation structures. It also means confronting biases in trial design, outreach, and eligibility criteria.
Efforts to improve inclusion must include structural changes to funding. Many trials operate under tight budgets that do not prioritize participant support. Funders and sponsors hold the power to change that. Budgeting for comprehensive financial assistance (transportation, internet stipends, and caregiver compensation) should be as standard as budgeting for lab tests. Building this into the financial structure of a trial sends a clear signal about whose needs matter.
Reimagining Trial Access Through Inclusive Practices
Patient trust is earned through clarity, respect, and meaningful support. Clear, plain-language materials about what costs are covered, how to access support, and what to expect financially can reduce anxiety and encourage participation. People should never have to guess whether they will be reimbursed, or fear unexpected costs. Open communication builds partnerships that are sustainable and informed, rather than extractive.
The lack of transparency in costs can also affect whether people stay in a study. Unclear reimbursement timelines, confusing policies, or the burden of fronting expenses can all lead to dropout. Addressing these barriers improves not just enrollment, but also retention and data quality. When people understand what participation will cost them in money and time before they enroll, fewer leave later. Embedding patient feedback throughout the trial process keeps solutions grounded in lived reality, and when patients are invited to co-design financial support strategies, those strategies are more likely to succeed.
Supporting equitable access means taking a hard look at systemic barriers and actively removing them. Financial support is not charity. It is justice. Making clinical trials fair and representative benefits everyone. Stronger data, faster recruitment, and better outcomes are all tied to who can afford to show up. That is why rethinking financial models is not just a patient advocacy issue. It is a scientific one.
Trial Access Designed Around People
To move forward, the clinical trial community must embrace an inclusive model grounded in empathy and evidence. Trial design must reflect the real-life circumstances of the people it hopes to serve. Financial support structures must anticipate needs rather than react to them, and community input must shape every step of the process.
More resources are now available for trial organizers looking to improve trial access. There is no shortage of ideas, only a shortage of will. The cost of inaction is high: underrepresentation, mistrust, and flawed science. Investing in participant support is not a luxury. It is the foundation of ethical research. See what trialport does for sponsors and CROs.
About the author
Keith Berelowitz has spent more than twenty years watching clinical trials work on paper and struggle in real life. He has helped run studies, advises sponsors and CROs on how they engage with people, and chairs a UK research ethics committee, where consent forms and participant information sheets cross his desk every month. That vantage point led to one conclusion: most trial problems are not failures of science. They are failures of understanding at the moment a person decides.
He founded trialport, a clinical trial navigation and decision-support platform, on a principle he brings from the ethics committee: clarity is an ethical issue, not only a communication one. People should understand what they are being asked to consider before they are asked to decide. Understanding comes first. Decisions follow.